Biovista and DART Therapeutics Enter into Drug Repositioning Collaboration Targeting Duchenne Muscular Dystrophy

March 26, 2013Press Releases

CHARLOTTESVILLE, Virginia and CAMBRIDGE, Massachusetts, March 26, 2013 /PRNewswire/ — DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy (DMD), and Biovista, a leader in systematic drug repositioning, announced today that they have entered into a research collaboration to identify and develop novel drug repositioning candidates for DMD … Read More

Biovista – NIH/DAIDS Seminar on use of MoA to predict Safety Signals

March 26, 2013Events

Biovista announces that its President, Dr. Aris Persidis, will give a seminar at the NIH/DAIDS Medical Officer’s Safety Forum on Thursday, March 28th. The seminar, is entitled “Using Mechanism of Action to Predict Safety Signals and Understanding Sub-Populations.” With the web being increasingly used to determine side effects of drugs, and with self-reporting patient social networking databases … Read More